欧洲委员会批准Takeda重新组合的ADAMTS13疗法(ADZYNMA),治疗一种罕见的疾病CTTP。 European Commission approves Takeda's recombinant ADAMTS13 therapy (ADZYNMA®) for cTTP, a rare disease.

欧洲委员会批准ADZYNMA® (复合ADAMTS13) 作为第一个用于治疗先天性血栓性血栓性斑 (cTTP) 的复合ADAMTS13替代疗法,为罕见病患者提供了新的治疗选择. European Commission approves ADZYNMA® (recombinant ADAMTS13) as the first recombinant ADAMTS13 replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP), offering a new treatment option for rare disease patients. Takeda的产品是欧盟内用于CTTP的唯一一种酶替代疗法,在证明有利于安全和功效后,在第三阶段试验中得到了批准。 Takeda's product, the only enzyme replacement therapy for cTTP in the EU, received approval after demonstrating favorable safety and efficacy results in a Phase 3 trial.